PH12015502086A1 - Ablative immunotherapy - Google Patents
Ablative immunotherapyInfo
- Publication number
- PH12015502086A1 PH12015502086A1 PH12015502086A PH12015502086A PH12015502086A1 PH 12015502086 A1 PH12015502086 A1 PH 12015502086A1 PH 12015502086 A PH12015502086 A PH 12015502086A PH 12015502086 A PH12015502086 A PH 12015502086A PH 12015502086 A1 PH12015502086 A1 PH 12015502086A1
- Authority
- PH
- Philippines
- Prior art keywords
- pathogen
- tumor
- immunotherapy
- apoptosis
- necrosis
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 244000052769 pathogen Species 0.000 abstract 4
- 230000001717 pathogenic effect Effects 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000735 allogeneic effect Effects 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 230000017074 necrotic cell death Effects 0.000 abstract 2
- 238000002679 ablation Methods 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 238000000315 cryotherapy Methods 0.000 abstract 1
- 238000004520 electroporation Methods 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002427 irreversible effect Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000037452 priming Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Thl mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Thl cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/796,171 US9320794B2 (en) | 2006-11-13 | 2013-03-12 | Ablative immunotherapy |
| PCT/US2014/022287 WO2014164396A1 (en) | 2013-03-12 | 2014-03-10 | Ablative immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015502086A1 true PH12015502086A1 (en) | 2016-01-18 |
Family
ID=51658863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502086A PH12015502086A1 (en) | 2013-03-12 | 2015-09-11 | Ablative immunotherapy |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2970910A4 (en) |
| JP (1) | JP6538647B2 (en) |
| KR (1) | KR102265276B1 (en) |
| CN (2) | CN105102613A (en) |
| AU (2) | AU2014249374A1 (en) |
| BR (1) | BR112015022974A8 (en) |
| CA (1) | CA2904853A1 (en) |
| IL (1) | IL241326B (en) |
| PH (1) | PH12015502086A1 (en) |
| SG (2) | SG11201507350WA (en) |
| WO (1) | WO2014164396A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110151309B (en) * | 2018-02-14 | 2022-02-15 | 上海美杰医疗科技有限公司 | Preoperative planning method and equipment for multi-modal ablation therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277368B1 (en) * | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
| CN1806849A (en) * | 2005-01-19 | 2006-07-26 | 上海三维生物技术有限公司 | Method of treating tumors |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| US20080112963A1 (en) * | 2006-11-13 | 2008-05-15 | Immunovative Therapies, Ltd. | Ablative immunotherapy |
| WO2009095033A1 (en) * | 2008-01-31 | 2009-08-06 | Agirx Limited | Vaccine compositons |
-
2014
- 2014-03-10 SG SG11201507350WA patent/SG11201507350WA/en unknown
- 2014-03-10 CN CN201480014494.7A patent/CN105102613A/en active Pending
- 2014-03-10 AU AU2014249374A patent/AU2014249374A1/en not_active Abandoned
- 2014-03-10 JP JP2016500938A patent/JP6538647B2/en active Active
- 2014-03-10 SG SG10201707446PA patent/SG10201707446PA/en unknown
- 2014-03-10 CN CN201710016168.5A patent/CN106581673A/en active Pending
- 2014-03-10 EP EP14779681.7A patent/EP2970910A4/en not_active Ceased
- 2014-03-10 BR BR112015022974A patent/BR112015022974A8/en not_active Application Discontinuation
- 2014-03-10 CA CA2904853A patent/CA2904853A1/en not_active Abandoned
- 2014-03-10 KR KR1020157028277A patent/KR102265276B1/en active IP Right Grant
- 2014-03-10 WO PCT/US2014/022287 patent/WO2014164396A1/en active Application Filing
-
2015
- 2015-09-08 IL IL241326A patent/IL241326B/en active IP Right Grant
- 2015-09-11 PH PH12015502086A patent/PH12015502086A1/en unknown
-
2020
- 2020-02-21 AU AU2020201309A patent/AU2020201309A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022974A2 (en) | 2017-07-18 |
| SG10201707446PA (en) | 2017-10-30 |
| AU2020201309A1 (en) | 2020-03-12 |
| EP2970910A1 (en) | 2016-01-20 |
| KR20150138234A (en) | 2015-12-09 |
| KR102265276B1 (en) | 2021-06-16 |
| CA2904853A1 (en) | 2014-10-09 |
| BR112015022974A8 (en) | 2019-11-26 |
| SG11201507350WA (en) | 2015-10-29 |
| IL241326A0 (en) | 2015-11-30 |
| WO2014164396A1 (en) | 2014-10-09 |
| IL241326B (en) | 2021-05-31 |
| AU2014249374A1 (en) | 2015-09-24 |
| CN106581673A (en) | 2017-04-26 |
| JP6538647B2 (en) | 2019-07-03 |
| JP2016518319A (en) | 2016-06-23 |
| EP2970910A4 (en) | 2016-11-16 |
| CN105102613A (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007095A (en) | Devices and the use thereof in methods for ablation therapy. | |
| GB201120779D0 (en) | Cancer therapy | |
| CO2017010662A2 (en) | Medical device to ablate tissue cells in a given treatment region | |
| WO2014153082A3 (en) | Systems and methods for treating prostate cancer | |
| MX2015003643A (en) | Method of treating cancer. | |
| HK1222309A1 (en) | Electrosurgical forceps for delivering rf and/or microwave energy into biological tissue rf / | |
| HK1222311A1 (en) | Electrosurgical apparatus for generating radiofrequency energy and microwave energy for delivery into biological tissue | |
| MX2017003246A (en) | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics. | |
| BR112014000949A2 (en) | apparatus for generating therapeutic impact waves and applications thereof | |
| EP4279003A3 (en) | Vapor ablation systems | |
| MX2018005117A (en) | Apparatuses for securing a medical device and related methods thereof. | |
| JP2014533743A5 (en) | ||
| PL2288413T3 (en) | Therapeutic device combining radiation therapy and thermotherapy | |
| MX2017006076A (en) | Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme. | |
| PH12015502086A1 (en) | Ablative immunotherapy | |
| CL2018002438A1 (en) | Method and composition for the treatment of cancer or a skin lesion using a vaccine. | |
| WO2014145498A3 (en) | Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase) | |
| BR112015013863A2 (en) | p16ink4a-derived peptides for prophylaxis and therapy of hpv-associated tumors and other p16-expressing tumors | |
| PH12017500754A1 (en) | Cancer and skin lesion treatment | |
| Moghadam et al. | A brief review of Hyperthermia as a neoadjuvant therapy method related to cancer treatment | |
| Doornaert et al. | Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: In response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo) radiation. Oral Oncol 2012; 48 (9): 905-11 | |
| NZ742470A (en) | Combination therapy for cancer | |
| Thompson Jr | Focal Therapy of Prostate Cancer-The Challenge | |
| WO2012151373A9 (en) | Rf induced thermal treatment of tissue pain | |
| Yan et al. | WITHDRAWN: Expression of the angiotensin II, rac GTPase activating protein 1, signal transducer and activator of transcription 3 signaling pathway in patients with permanent atrial fibrillation and rheumatic heart disease |